Ublituximab Global Market Report 2026

Ublituximab is a monoclonal antibody engineered to target the CD20 protein present on the surface of B-cells, helping to decrease abnormal or overactive B-cell activity. It functions by attaching to these cells and promoting their elimination through immune system processes such as antibody-dependent cellular cytotoxicity. It is primarily developed for the treatment of certain blood cancers, helping to regulate immune responses and manage disease progression effectively.

The primary formulation types of ublituximab include intravenous (IV) and pre-filled syringes. Intravenous administration delivers medications or fluids directly into the bloodstream through a vein, enabling rapid and controlled treatment. Ublituximab is indicated for conditions such as chronic lymphocytic leukemia, multiple sclerosis, and non-Hodgkin lymphoma. It is supplied through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by end-users such as hospitals, specialty clinics, and research institutes.

Tariffs are impacting the ublituximab market by increasing costs of imported biologic raw materials, cell culture media, specialized manufacturing equipment, and cold-chain logistics components. North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces cost pressures in biologic exports. These tariffs are increasing production and distribution costs for monoclonal antibody therapies. However, they are also driving investment in domestic biologics manufacturing facilities, localized supply chains, and improved production efficiencies to support long-term market stability.

The ublituximab market research report is one of a series of new reports from The Business Research Company that provides ublituximab market statistics, including ublituximab industry global market size, regional shares, competitors with a ublituximab market share, detailed ublituximab market segments, market trends and opportunities, and any further data you may need to thrive in the ublituximab industry. This ublituximab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ublituximab market size has grown rapidly in recent years. It will grow from $1.25 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to advances in monoclonal antibody development, increasing prevalence of b-cell related disorders, expansion of biologics manufacturing capacity, regulatory approvals for cd20 therapies, growth in immuno-oncology research.

The ublituximab market size is expected to see rapid growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing development of next-generation antibodies, rising focus on treatment durability and safety, expansion into autoimmune indications, growing investments in biologics manufacturing innovation, increasing adoption of precision immunotherapy. Major trends in the forecast period include increasing adoption of cd20-targeted monoclonal antibodies, rising focus on b-cell depletion therapies, growing use of immune-modulating treatments, expansion of combination antibody regimens, enhanced optimization of antibody engineering.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the ublituximab market in the coming years. Autoimmune disorders are conditions in which the immune system mistakenly attacks healthy cells or where blood cell production and function are disrupted. The rising occurrence of these disorders is largely attributed to enhanced diagnostic capabilities and greater awareness, as healthcare systems are now better able to detect previously undiagnosed cases through advanced testing methods and expanded screening programs. Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, helps manage autoimmune disorders by selectively depleting pathogenic B cells, thereby reducing abnormal immune activity and malignant cell proliferation. For example, in February 2024, according to Arthritis Australia, a non-profit organization based in Australia, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these numbers expected to increase by 2040 to approximately 280,040 males and 479,828 females. Consequently, the rising prevalence of autoimmune disorders is fueling the growth of the ublituximab market.

Major companies in the ublituximab market are prioritizing the development of innovative products like next-generation monoclonal antibodies to boost efficacy, cut side effects, and increase patient convenience. These next-generation monoclonal antibodies represent engineered versions with enhanced targeting, potency, or safety features, which improve treatment outcomes, lessen side effects, and enable simpler dosing regimens. For example, in January 2023, TG Therapeutics Inc., a US-based biopharmaceutical firm, introduced BRIUMVI (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis, featuring a one-hour infusion and a comprehensive patient support program to boost accessibility and adherence. The drug is a glycoengineered anti-CD20 monoclonal antibody that effectively depletes B-cells, lowering relapse rates and disease activity in RMS patients, while reducing potential side effects and delivering a more user-friendly dosing schedule than conventional treatments. Its mechanism of action entails binding to a distinct epitope on CD20-expressing B-cells, leading to their precise depletion via antibody-dependent cellular cytotoxicity (ADCC) and apoptosis, thereby regulating the autoimmune response that drives multiple sclerosis.

In August 2023, TG Therapeutics Inc., a US-based biopharmaceutical company offering ublituximab, collaborated with Neuraxpharm Holdco S.a.r.l. to market BRIUMVI beyond the US. Through this partnership, TG Therapeutics and Neuraxpharm seek to deliver BRIUMVI to patients internationally, capitalizing on Neuraxpharm's deep expertise in European neurology and its strong footprint in more than 20 countries for a swift and successful rollout, while TG gains from initial payments, milestone payments, graduated royalties on net sales, and the option to reclaim commercial rights if control changes. Neuraxpharm Holdco S.a.r.l. is a Germany-based pharmaceutical firm focused on therapies for central nervous system (CNS) disorders.

Major companies operating in the ublituximab market are Samsung Biologics Co. Ltd., TG Therapeutics Inc.

North America was the largest region in the ublituximab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ublituximab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ublituximab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ublituximab market consists of sales of azer-cel and tg-1701. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ublituximab Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ublituximab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ublituximab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ublituximab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Formulation Type: Intravenous; Pre-Filled Syringes
• 2) By Indication: Chronic Lymphocytic Leukemia; Multiple Sclerosis; Non-Hodgkin Lymphoma
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals; Specialty Clinics; Research Institutes
• Subsegments:
• 1) By Intravenous: Single Dose Vials; Multi Dose Vials; Lyophilized Powder; Liquid Solution
• 2) By Pre Filled Syringes: Standard Pre Filled Syringes; Safety Engineered Pre Filled Syringes; Disposable Pre Filled Syringes; Reusable Pre Filled Syringes
• Companies Mentioned: Samsung Biologics Co. Ltd.; TG Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.